Title | Niacin therapy improves outcome and normalizes metabolic abnormalities in an NAXD-deficient patient. |
Publication Type | Journal Article |
Year of Publication | 2022 |
Authors | Manor, J, Calame, DG, Gijavanekar, C, Tran, A, Fatih, JM, Lalani, SR, Mizerik, E, Parnes, M, Mehta, VP, Adesina, AM, Lupski, JR, Scaglia, F, Elsea, SH |
Journal | Brain |
Volume | 145 |
Issue | 5 |
Pagination | e36-e40 |
Date Published | 2022 Jun 03 |
ISSN | 1460-2156 |
Keywords | Cholesterol, HDL, Humans, Niacin |
DOI | 10.1093/brain/awac065 |
Alternate Journal | Brain |
PubMed ID | 35231119 |
Grant List | U54 HG006542 / HG / NHGRI NIH HHS / United States UM1 HG006542 / HG / NHGRI NIH HHS / United States R35 NS105078 / NS / NINDS NIH HHS / United States R01 CA211176 / CA / NCI NIH HHS / United States T32 NS043124 / NS / NINDS NIH HHS / United States |
Niacin therapy improves outcome and normalizes metabolic abnormalities in an NAXD-deficient patient.
Similar Publications
A genetic association study of circulating coagulation factor VIII and von Willebrand factor levels. Blood. 2024;143(18):1845-1855. | .
Identification of potent pan-ephrin receptor kinase inhibitors using DNA-encoded chemistry technology. Proc Natl Acad Sci U S A. 2024;121(19):e2322934121. | .
Exome sequencing implicates ancestry-related Mendelian variation at SYNE1 in childhood-onset essential hypertension. JCI Insight. 2024;9(9). | .